↓ Skip to main content

Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?

Overview of attention for article published in BMC Infectious Diseases, February 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

twitter
10 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
13 Mendeley
Title
Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?
Published in
BMC Infectious Diseases, February 2017
DOI 10.1186/s12879-017-2199-x
Pubmed ID
Authors

Antonio Di Biagio, Marta Ameri, Davide Sirello, Giovanni Cenderello, Enrico Di Bella, Lucia Taramasso, Barbara Giannini, Mauro Giacomini, Claudio Viscoli, Giovanni Cassola, Marcello Montefiori

Abstract

In the last 20 years routine T CD4+ lymphocyte (CD4+) cell count has proved to be a key factor to determine the stage of HIV infection and start or discontinue of prophylaxis for opportunistic infections. However, several studies recently showed that in stable patients on cART a quarterly CD4+ cell count monitoring results in limited (or null) clinical relevance. The research is intended to investigate whether performing quarterly CD4+ cell counts in stable HIV-1 patients is still recommendable and to provide a forecast of the cost saving that could be achieved by reducing CD4+ monitoring in such a category of patients. The study is based on data referring to all HIV-infected patients > 18 years of age being treated at two large infectious diseases units located in the metropolitan area of Genoa, Italy. The probability of CD4+ cell counts dropping below a threshold value set at 350 cells/mm(3) is assessed using confidence intervals and Kaplan-Meier survival estimates, whereas multivariate Cox analysis and logistic regression are implemented in order to identify factors associated with CD4+ cell count falls below 350 cells/mm(3). Statistical analysis reveals that among stable patients the probability of maintaining CD4+ >350 cell/mm(3) is more than 98%. Econometric models indicate that HCV co-infection and HIV-RNA values >50 copies/mL in previous examinations are associated with CD4+ falls below 350 cells/mm(3). Moreover, results suggest that the cost saving that could be obtained by reducing CD4+ examinations ranges from 33 to 67%. Empirical findings shows that patients defined as stable at enrollment are highly unlikely to experience a CD4+ value <350 cell/mm(3) in the space/arc of a year. The research supports a recommendation for annual CD4+ monitoring in stable HIV-1 patients.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 8%
Unknown 12 92%

Demographic breakdown

Readers by professional status Count As %
Unspecified 4 31%
Researcher 3 23%
Student > Ph. D. Student 2 15%
Other 2 15%
Lecturer > Senior Lecturer 2 15%
Other 0 0%
Readers by discipline Count As %
Unspecified 5 38%
Medicine and Dentistry 4 31%
Social Sciences 2 15%
Biochemistry, Genetics and Molecular Biology 1 8%
Engineering 1 8%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2017.
All research outputs
#1,880,339
of 9,679,413 outputs
Outputs from BMC Infectious Diseases
#672
of 4,116 outputs
Outputs of similar age
#80,325
of 315,729 outputs
Outputs of similar age from BMC Infectious Diseases
#53
of 134 outputs
Altmetric has tracked 9,679,413 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,116 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,729 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 134 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.